Sign In
Buy PTGX
$95.41
+2.18 (+2.34%)
At Close: Jun 03, 2026
Protagonist Therapeutics (PTGX) Tops Q4 Earnings and Revenue Estimates
09:35am, Friday, 21'st Feb 2025
Protagonist Therapeutics (PTGX) came out with quarterly earnings of $1.98 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.44 per share a year ago.
Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
07:00am, Friday, 21'st Feb 2025
$165.0 million icotrokinra (formerly JNJ-2113) milestone earned in Q4 2024, received in January 2025 PN-881, a potential best-in-class oral IL-17 receptor antagonist peptide nominated as a development
Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck
05:55am, Monday, 13'th Jan 2025
Positive results achieved from both ICONIC studies using JNJ-2113 for the treatment of patients with moderate-to-severe plaque psoriasis; Superiority study is data expected in Q2 of 2025. Topline resu
Protagonist Therapeutics Reports Granting of Inducement Awards
04:05pm, Monday, 06'th Jan 2025
NEWARK, CALIFORNIA / ACCESSWIRE / January 6, 2025 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on January 2, 2025, it issued inducement awards to Newman Yeilding, M.D., upon his
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
04:05pm, Thursday, 19'th Dec 2024
NEWARK, CA / ACCESSWIRE / December 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.
Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024
07:30am, Friday, 22'nd Nov 2024
NEWARK, CA / ACCESSWIRE / November 22, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
07:30am, Tuesday, 19'th Nov 2024
Webcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information below NEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist
Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know
01:06pm, Wednesday, 13'th Nov 2024
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates
06:30pm, Thursday, 07'th Nov 2024
Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.58 per share a year ago.
Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update
04:05pm, Thursday, 07'th Nov 2024
Top line results for JNJ-2113 Phase 3 ICONIC-LEAD and Phase 3 ICONIC-TOTAL clinical trials in patients with moderate to severe psoriasis expected in Q4 2024 Top line results for JNJ-2113 Phase 2b ANTH
NEWARK, CA / ACCESSWIRE / November 5, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that final data from the Phase 2 REVIVE study with rusfertide in polycythemia ver
Protagonist Therapeutics (PTGX) is on the Move, Here's Why the Trend Could be Sustainable
09:51am, Tuesday, 15'th Oct 2024
If you are looking for stocks that are well positioned to maintain their recent uptrend, Protagonist Therapeutics (PTGX) could be a great choice. It is one of the several stocks that passed through ou
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
01:17pm, Tuesday, 10'th Sep 2024
Truist Securities initiated coverage on Protagonist Therapeutics Inc PTGX, citing its first-in-class lead asset with encouraging Phase 2 data in a rare form of blood cancer and a multi-billion dollar
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
07:30am, Tuesday, 03'rd Sep 2024
NEWARK, CA / ACCESSWIRE / September 3, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates
09:21am, Tuesday, 06'th Aug 2024
Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.50 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.68 per share a year ago.
